Journal of Cancer Therapy
Vol.4 No.7(2013), Paper ID 36587, 6
pages
DOI:10.4236/jct.2013.47144
Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model
Mieko Yanagisawa, Keigo Yorozu, Mitsue Kurasawa, Yoichiro Moriya, Naoki Harada
Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan
Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan
Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan
Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan
Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan
Copyright © 2013 Mieko Yanagisawa, Keigo Yorozu, Mitsue Kurasawa, Yoichiro Moriya, Naoki Harada et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
M. Yanagisawa, K. Yorozu, M. Kurasawa, Y. Moriya and N. Harada, "Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model,"
Journal of Cancer Therapy, Vol. 4 No. 7, 2013, pp. 1236-1241. doi:
10.4236/jct.2013.47144.